

Financial Tear Sheet

Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Stock Information

XBIT (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$4.31
Change (%)	▲ 0.01 (0.23%)
Volume	13,552
52 Week Low	\$3.55
Market Cap	\$152,735,020
Rolling EPS	-0.77
PE Ratio	0
Shares Outstanding	35,519,772
Data as of 07/18/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
07/10/18	XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa
05/22/18	XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
04/16/18	XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

Upcoming Events

There are currently no events scheduled.

SEC Filings

Primary IR Contact

Filing Date	Form
06/21/18	4/A
06/21/18	4
06/21/18	4
06/21/18	4

James S. Whitehurst
 XBiotech
Phone: +1 512.386.2993
Email: swhitehurst@xbiotech.com

Management

John Simard Founder, President, Chief Executive Officer & Chairman

Norma I. Gonzalez Vice President of Quality

Queenana Han, C.P.A., C.G.A. Vice President of Finance and Human Resources and Secretary

Sushma Shivaswamy, Ph.D. Chief Scientific Officer

Board of Directors

John Simard Founder, President, Chief Executive Officer & Chairman

Thorpe McKenzie Director

Jan-Paul Waldin Director

Donald H. MacAdam Director